Xencor

$48.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.15 (+0.31%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Xencor and other stocks, options, and ETFs commission-free!

About XNCR

Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA. The listed name for XNCR is Xencor, Inc. Common Stock.

CEO
Bassil I. Dahiyat
Employees
166
Headquarters
Monrovia, California
Founded
1997
Market Cap
2.89B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
228.10K
High Today
$54.99
Low Today
$47.59
Open Price
$54.99
Volume
302.57K
52 Week High
$55.33
52 Week Low
$19.35

XNCR News

BenzingaFeb 23

Recap: Xencor Q4 Earnings

Shares of Xencor (NASDAQ:XNCR) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 48.94% year

XNCR Earnings

-$0.61
-$0.45
-$0.30
-$0.14
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.38 per share
Actual
-$0.24 per share
Replay Earnings Call

You May Also Like

HA
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure